Eriksson, Carl http://orcid.org/0000-0002-1046-383X
Söderling, Jonas
Karlqvist, Sara
Bröms, Gabriella
Everhov, Åsa H.
Bergemalm, Daniel
Ludvigsson, Jonas F.
Olén, Ola
Halfvarson, Jonas
,
Funding for this research was provided by:
Janssen Pharmaceuticals (CNTO1275CRD0005)
Örebro University
Article History
Received: 12 September 2022
Accepted: 21 February 2023
First Online: 17 March 2023
Declarations
:
: CE received grant support/lecture fee/advisory board from Takeda, Janssen Cilag, Pfizer, Abbvie. SK received a lecture fee from Takeda. GB has served as a speaker for Takeda and worked on projects at Karolinska Institutet, partly financed by Janssen and Pfizer. ÅE has worked on projects at Karolinska Institutet and SWIBREG, partly financed by grants from Ferring and Janssen. JFL coordinates a study on behalf of the Swedish IBD quality register (SWIBREG). That study has received funding from the Janssen corporation. OO has been PI on projects at Karolinska Institutet partly financed by investigator-initiated grants from Janssen and Ferring, and also report a grant from Pfizer in the context of a national safety monitoring program. None of these studies have any relation to the present study. Karolinska Institutet has received fees for lectures and participation on advisory boards by OO from Janssen, Ferring, Takeda and Pfizer on topics not related to the present study. JH has served as a speaker, a consultant and/or an advisory board member for Abbvie, Celgene, Celltrion, Ferring, Hospira, Janssen, Medivir, MSD, Olink Proteomics, Pfizer, Prometheus Laboratories Inc., RenapharmaVifor, Sandoz, Shire, Takeda, Thermo Fisher and Tillotts Pharma. JH also received research funding from Janssen, MSD and Takeda. MS and SM have no conflicts to report.
: Ethical approval for this study was granted by the Regional Ethics Committee, Karolinska Institute, Stockholm, Sweden (2007/785-31/5, 2011/1509-32, 2015/0004-31, 2015/2237-32, 2017/1959-32).